The Latest News
Surefire Medical Launches Advanced Precision Direct-To-Tumor Infusion System at CIRSE
CareSync Secures $18 Million in Series B Funding. Investment to support rapid expansion, reinforce market-leading position. Investment round led by Merck Global Health Innovation Fund (Merck GHI), Greycroft Partners, and Harbert Venture Partners, as well as existing investors including Tullis Health Investors.
Two Members of the Tullis Health Investors Advisory Board, Dr. David Leffell and Dr. Barbara Bierer, Become Venture Partners>
Tullis Health Investors is pleased to announce that Dr. David Leffell, Chair of the Tullis Health Investors Advisory Board, and Dr. Barbara Bierer, a long-time member of the Board, have each taken additional responsibilities as Venture Partners of Tullis.
In June 2015, Tullis Growth Fund, L.P. (TGF) closed an investment into Surefire Medical. The company develops, manufactures, and markets medical devices, in particular catheters to precisely deliver therapeutic drugs in liver cancer patients.
Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases.
We are pleased to announce that Professor Das Narayandas, BTech, PGDM, PhD, has joined the Advisory Board of Tullis Health Investors. Das Narayandas is the James J. Hill Professor of Business Administration at the Harvard Business School. He is currently the Senior Associate Dean, Chair, Harvard Business Publishing, and Senior Associate Dean, Chair, Executive Education.
The Tullis Growth Fund has completed its second investment into Orthosensor, a Florida-based maker of knee and joint implant placement technologies.
CareSync, a pioneer in patient-centered care coordination, announced today it has secured $5 million in Series A financing led by Tullis Health Investors, Clearwell Group, CDH Solutions, and CareSync Founder & CEO, Travis Bond.
Valeritas, Inc., a leader in simple, disposable basal-bolus insulin delivery technology designed for patients with Type 2 diabetes, announced today that it has received a 2014 Cardinal Health Supply Chain Excellence Award. The award was presented October 16th at Cardinal's annual Business Partners Conference in Columbus, Ohio.
Synageva BioPharma Corp. ("Synageva") (GEVA), a biopharmaceutical company developing therapeutic products for rare disorders announced today the appointment of Robert Bazemore as Chief Operating Officer. Reporting directly to Sanj K. Patel, President and Chief Executive Officer, Robert will oversee the planned global commercial launch of the company's lead program, sebelipase alfa for LAL Deficiency, and will have responsibility for the company's global commercial, market access and medical affairs operations.
Exagen Diagnostics Inc. has filed its S-1 form with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO). No terms were given for the offering, but it has the potential to raise up to $69 million. The company plans to list on the Nasdaq Global Market under the symbol of EXDX. The underwriters for this initial offering are Leerink Partners, William Blair and Baird.
ElectroCore’s funding is $10 million oversubscribed by all parties including Merck’s GHI fund to bring it to $50 million>
electroCore, the New Jersey based electroceutical company has announced that its successful funding initiative of $40 million, announced in April last year, has been oversubscribed by $10 million by all parties including Merck’s Global healthcare Innovation fund and private equity groups Easton Capital and Core Ventures. The final tranche of $15 million of the $40 million was optional but following discussions between the investors this was not only made compulsory but increased by $10 million to a total of $50 million.
Synageva BioPharma™ Highlights Data Presentations And Satellite Symposium At The European Atherosclerosis Society Congress>
Synageva BioPharma Corp. (Synageva) (GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, today announced data presentations and a company-sponsored satellite symposium at the European Atherosclerosis Society (EAS) Congress being held May 31-June 3, 2014 in Madrid, Spain.
Interim Analysis Suggests that Delivery of Insulin via Valeritas' V-Go® Shows Promise in Improving Glycemic Control for Patients with Type 2 Diabetes Previously Taking Long-Acting Insulin>
Valeritas, makers of the V-Go® Disposable Insulin Delivery Device, announced interim analysis data from SIMPLE, a prospective observational study, today that suggest patients with Type 2 diabetes who switched to V-Go therapy from their previous baseline treatment of long-acting insulin with or without oral medications experienced significantly improved glycemic control and a reduction in total daily insulin dose. The interim results, part of a planned interim analysis performed as part of the twelve month study, were presented at the American Association of Clinical Endocrinologists (AACE) 23rd annual scientific and clinical congress.
Following a successful proof of concept assessment in patients with gastroparesis, a clinical trial is commencing to treat patients with two of the most common gastrointestinal (“GI”) complaints, Irritable Bowel Syndrome (“IBS”) and functional dyspepsia. The trial, which is being held at the Royal Free Hospital in London, is a double-blind, parallel, sham- controlled trial involving 80 patients, using electroCore’s non-invasive vagus nerve stimulation (nVNS) therapy. Results are expected in the first quarter of 2015.
SupplyPro, Inc., announced today the launch of SupplyScale, a flexible weight-based inventory management solution that can be seamlessly integrated into a new or existing SupplyPro system.
Craig Giangregorio, an award-winning customer service professional with extensive software and engineering experience, has joined SupplyPro, Inc., a leading provider of inventory management solutions in a wide range of industries.